Tumor biology could guide mantle cell lymphoma treatment from the time of diagnosis

Today, treatment decisions for patients with mantle cell lymphoma are heavily based on age alone, although the disease can range from slow-growing (indolent) to very aggressive. In a new journal article, Ingrid Glimelius and co-authors suggest that it is time to let the disease's biology also guide treatment—and provide more effective interventions earlier for those at the highest risk of aggressive disease, while avoiding unnecessarily intensive treatment for patients with indolent disease.

≈